Latest News
Arvinas, Inc.
- First PROTAC protein degrader approval advances targeted protein degradation, Arvinas states
- Arvinas Fell While It Turned A Profit
- Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
- Arvinas presents phase 1 data for Parkinson’s drug ARV-102 By Investing.com
- Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
- 252,939 Shares in Arvinas, Inc. $ARVN Acquired by Bank of America Corp DE
- Arvinas (NASDAQ:ARVN) Shares Climb 6.3% - What's Next?
- Arvinas enters immuno-oncology with HPK1 PROTAC degrader in Phase I/II trial
- Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Arvinas Announces First Patient Dosed in Phase 1/2 Clinical
- Arvinas doses first patient in ARV-6723 cancer trial By Investing.com
- Arvinas Q2 2026 Earnings Call Transcript
Headlines from the last 30 days, linking to the original publishers. See all market news →